BUSINESS
    Sanofi Looks to Join Top 3 in Japan Pharma Market by 2030
    April 25, 2025
    Sanofi aims to become a top three pharmaceutical company in terms of Japan revenue by 2030 by continuing its double-digit growth towards the end of the decade, the company’s country president Takahiko Iwaya said on…

    LATEST

    Sanofi’s Dupixent Filed for Bullous Pemphigoid in Japan
    April 28, 2025
    Sanofi said on April 25 that it has filed its IL-4/IL-13 inhibitor Dupixent (dupilumab) for an additional indication of bullous pemphigoid in Japan. If approved, the drug will be the country’s first biologic agent to…
    ASKA’s Contraceptive, Vabysmo Label Expansion Now in Line for Japan Approval
    April 28, 2025
    ASKA Pharmaceutical’s contraceptive pill drospirenone cleared the review of a key health ministry panel on April 25, along with the label expansions of two products, setting the stage for Japanese regulatory approval.The Pharmaceutical Affairs Council’s…
    LDP Members Raise No Call for Tax Cuts, Fret Inflationary Impact on Medical Facilities: Fiscal Reform HQ
    April 25, 2025
    While talks of consumption tax cuts swirl in Japan ahead of the Upper House election this summer, lawmakers of the ruling Liberal Democratic Party (LDP) made no clear demand for reducing the rate of such…

    COMMENTARY

    How Will Japan Deal with Expected Cost Spike with Japan-Made Antibiotic APIs?
    By Takashi Ebisawa

    Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…

    COLUMN

    Build a Strong Employer Brand - What Can You Do If Your Company Stinks?
    By Philip Carrigan

    Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…

    Discussions on Next PMD Act Amendment

    Japan Cabinet Approves Bill to Amend PMD Act

    The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

    Drug Approval & Reimbursement in 2024

    Japan Approves Zepbound, Qalsody, and Lots More Drugs

    Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

    Chuikyo Debate on Off-Year Drug Price Revisions

    Chuikyo OKs Outline of FY2025 Off-Year Drug Price Revision
    By Ken Yoshino

    Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…

    TRENDS

    Top 10 PHARMA JAPAN Articles of 2024

    For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…

    MHLW Panel on Generic Industry Structure

    MHLW Panel Draws Up Plans for Generic Industry Shakeup in Final Report

    A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…

    MHLW Panel on Pharmaceutical Regulations

    Regulation Panel’s Final Report Specifies Exemptions for All-Case PMS

    The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…

    Chuikyo on FY2024 Reimbursement Reform

    Chuikyo OKs Outline of FY2024 Drug Pricing Reform; No Unprofitability Re-Pricing for 7%-Plus Price Gap

    Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

    MHLW Expert Panel on Comprehensive Policies

    Expert Panel Broadly OKs Draft Report on Pharma Policies, Further Deliberations by Other Forums
    By Yoshinori Sagehashi

    The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…

    NEWS CATEGORY

    REGULATORY

    BUSINESS

    ORGANIZATION

    ACADEMIA